An Open-Label, Phase Ii Study Of Patritumab Deruxtecan (Her3-Dxd, U3-1402) In Patients (Pts) With Previously Treated Advanced/Metastatic Colorectal Cancer (Crc).

Kanwal Pratap Singh Raghav,Takayuki Yoshino,Hiroya Taniguchi,Sabine Tejpar,Arndt Vogel,Zev A. Wainberg,Kensei Yamaguchi,Masayuki Kanai,Yali Liu,Sabeen Mekan, Geetha Pudussery,Yang Qiu,Scott Kopetz

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 3|浏览2

暂无评分

摘要

TPS157Background: Patritumab deruxtecan (HER3-DXd; U3-1402) is a novel, investigational antibody drug conjugate comprising an anti-HER3 monoclonal antibody, a tetrapeptide-based linker, and a topoi...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要